Chloropeptins I and II, novel inhibitors against gp120-CD4 binding from Streptomyces sp.

The Journal of Antibiotics
1994.0

Abstract

We previously reported isochromophilones I and II from Penicillium sp. as the first microbial-origin inhibitors against gpl20-CD4 binding. Now, we report two additional inhibitors, chloropeptins I (1) and II (2), produced by a soil actinomycete Streptomyces sp. WK-3419. Compound 1 is a new compound, while 2 was identified as complestatin (known to inhibit hemolysis of erythrocytes sensitized by the complement system). This communication deals with their fermentation, isolation, characterization, and biological activities. The inhibitory activities against gpl20-CD4 binding were monitored by ELISA. A seed culture of Streptomyces sp. WK-3419 was prepared, and then transferred to a 50-liter jar fermentor for production. The mycelium cake from the cultured broth was extracted with 70% aqueous acetone, followed by solvent extraction (ethyl acetate at pH 2), silica gel column chromatography, and HPLC (Shiseido Capcell pak C18-SG column) to obtain 1 (111 mg, yellow powder) and 2 (67 mg, yellow powder). The physicochemical properties of 1 were as follows: mp >300°C; [α]₂₆⁰ -18.7° (c=0.16, DMSO); UV λₙₘ (ε): 214 (64,600), 239(sh), 285(sh), 291(14,600), and 304(sh); molecular formula C₆₁H₄₅N₇O₁₅Cl₆ (determined by HRFAB-MS). The structure of 1 was determined by comparison with 2 (complestatin) via NMR: three aromatic proton signals of 1's indole moiety indicated that C-7 of the indole ring is conjugated to an adjacent phenol group, so 1 was named chloropeptin I. Compounds 1 and 2 inhibited gpl20-CD4 binding with IC₅₀ values of 2.0 μM and 3.3 μM, respectively. They showed no antimicrobial activity against various bacteria and fungi at 1.0 mg/ml, and no cytotoxicity against B-16 melanoma at 20 μM. Compound 1 significantly inhibited HIV replication in peripheral human lymphocytes at 7.5 μM without affecting cell proliferation. Both 1 and 2 were found to inhibit the binding between gpl20 and CD4 and exhibit selective anti-HIV activities, which may block HIV entry into lymphocytes (complestatin (2) was previously reported to inhibit HIV-1-induced cytopathicity and syncytium formation in CD4+ T-lymphocytes). The structure elucidation of 1 will be reported elsewhere.

Knowledge Graph

Similar Paper

Chloropeptins I and II, novel inhibitors against gp120-CD4 binding from Streptomyces sp.
The Journal of Antibiotics 1994.0
Chloropeptins, New Anti-HIV Antibiotics Inhibiting gp120-CD4 Binding from Streptomyces sp. I. Taxonomy, Fermentation, Isolation, and Physico-chemical Properties and Biological Activities.
The Journal of Antibiotics 1997.0
Chloropeptins, New Anti-HIV Antibiotics Inhibiting gp120-CD4 Binding from Streptomyces sp. II. Structure Elucidation of Chloropeptin I.
The Journal of Antibiotics 1997.0
The Complestatins as HIV-1 Integrase Inhibitors. Efficient Isolation, Structure Elucidation, and Inhibitory Activities of Isocomplestatin, Chloropeptin I, New Complestatins, A and B, and Acid-Hydrolysis Products of Chloropeptin I
Journal of Natural Products 2001.0
Dinghupeptins A–D, Chymotrypsin Inhibitory Cyclodepsipeptides Produced by a Soil-Derived Streptomyces
Journal of Natural Products 2018.0
Quinoxapeptins: Novel Chromodepsipeptide Inhibitors of HIV-1 and HIV-2 Reverse Transcriptase. I. The Producing Organism and Biological Activity.
The Journal of Antibiotics 1996.0
Pepticinnamins, new farnesyl-protein transferase inhibitors produced by an actinomycete. I. Producing strain, fermentation, isolation and biological activity.
The Journal of Antibiotics 1993.0
Condensed aromatic peptide family of microbial metabolites, inhibitors of CD28–CD80 interactions
Bioorganic & Medicinal Chemistry Letters 2003.0
Clonostachin, a Novel Peptaibol That Inhibits Platelet Aggregation.
The Journal of Antibiotics 1997.0
Ahpatinins, new acid protease inhibitors containing 4-amino-3-hydroxy-5-phenylpentanoic acid.
The Journal of Antibiotics 1986.0